Thursday, Jun 14, 2001

Genentech Invites Public to Listen to Webcast of June 21 Discussion of Xanelim Phase III Results

South San Francisco, Calif. -- June 14, 2001 --

Genentech, Inc. (NYSE: DNA) invites investors and the general public to listen to a webcast of a discussion of Xanelim™ Phase III results for patients with moderate to severe plaque psoriasis that will be presented at the National Psoriasis Foundation® USA 2001 World Conference and the Second Joint Meeting of the International Psoriasis Symposium European Congress on Psoriasis on June 21, 2001. The webcast will begin at 6:00p.m. PDT. The webcast can be accessed by going to Genentech's website at and will be archived and available for replay through close of business on June 28, 2001.

An audio replay of the webcast will be available beginning at 8:00p.m. PDT on June 21, 2001 through the close of business on June 28, 2001. Access numbers for this replay are: 1-800-633-8284 (domestic) and 1-858-587-5842 (international); passcode number is 19137196.

Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. Fourteen of the currently approved biotechnology products stem from Genentech science. Genentech markets nine biotechnology products directly in the United States. The company has headquarters in South San Francisco, California and is traded on the New York Stock Exchange under the symbol DNA.

# # #